BNTX vs MRNA vs PFE vs NVAX vs ARCT

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus -51. 4% for Arcturus Therapeutics Holdings Inc. (ARCT). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate BioNTech SE (BNTX) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 3. 6x versus Pfizer Inc. at 19. 5x.

Over the past 5 years, Pfizer Inc.

(PFE) delivered a total return of -13. 3%, compared to -94. 8% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: BNTX returned +568. 1% versus NVAX's -90. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 54β versus Arcturus Therapeutics Holdings Inc. 's 2. 41β — meaning ARCT is approximately 344% more volatile than PFE relative to the S&P 500. On balance sheet safety, BioNTech SE (BNTX) carries a lower debt/equity ratio of 1% versus 78% for Pfizer Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus -51. 4% for Arcturus Therapeutics Holdings Inc. (ARCT). On earnings-per-share growth, the picture is similar: Novavax, Inc. grew EPS 306. 5% year-over-year, compared to -62. 8% for BioNTech SE. Over a 3-year CAGR, NVAX leads at -11. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -145. 2% for Moderna, Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -158. 1% for MRNA. At the gross margin level — before operating expenses — ARCT leads at 95. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ARCT: 152.

8% to $22. 50.

In this comparison, PFE (6.

5% yield) pays a dividend. BNTX, MRNA, NVAX, ARCT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pfizer Inc.

(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 6. 5% yield). Novavax, Inc. (NVAX) carries a higher beta of 2. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PFE: +29. 6%, NVAX: -90. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BNTX is a mid-cap quality compounder stock; MRNA is a mid-cap quality compounder stock; PFE is a mid-cap income-oriented stock; NVAX is a small-cap high-growth stock; ARCT is a small-cap quality compounder stock. PFE pays a dividend while BNTX, MRNA, NVAX, ARCT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.